RECRUITING

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Description

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Conditions

Atopic Dermatitis (AD)
Talk to us

Related Conditions:

Atopic Dermatitis (AD)

Study Overview

On this page

Study Details

Study overview

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Condition
Atopic Dermatitis (AD)
Intervention / Treatment

-

Contacts and Locations

Lancaster

Antelope Valley Clinical Trials, Lancaster, California, United States, 93534

North Miami Beach

Ziaderm Research LLC, North Miami Beach, Florida, United States, 33162

Winter Park

Conquest Research LLC, Winter Park, Florida, United States, 32789

Metairie

Clinical Trials Management, LLC, Metairie, Louisiana, United States, 70006

Woodbury

Vitality Clinical Trials LLC, Woodbury, New York, United States, 11797

Mayfield Heights

Apex Clinical Research Center, LLC, Mayfield Heights, Ohio, United States, 44124

Southlake

Stryde Research-Epiphany Dermatology, Southlake, Texas, United States, 76092

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
  • * Have moderate to severe disease not adequately controlled by topical treatments.
  • * Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.
  • * Have certain infections or other immune conditions.
  • * Recently used medications that could interfere with the study.
  • * Are pregnant or breastfeeding.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bluefin Biomedicine, Inc.,

Study Record Dates

2027-03-31